Meet Ori Biotech’s Jason Foster. How did he transition to advanced therapy, and why did he end up in the UK?

A drug development journey with origins in the 1950s has finally reached its successful conclusion: a new treatment for lupus.

Four courageous marketer-knights weigh in on what it takes to tilt against the social media windmills of pharma’s digital content kingdom.

Mike Rea of IDEA Pharma speaks frankly on the mud fights, echo chambers, and risks at play in the virtual forums of social media in 2021.

The EMA has given the nod to Ronapreve and Regkirona, two monoclonal antibody treatments for COVID-19.

Jan Cools of the VIB Center for Cancer Biology discusses his experience with Mission Bio’s new DNA sequencing platform.

After a madcap back and forth between leading and dissenting Democrats, Biden’s drug pricing reform plans have reached a compromised final form.

Stating an intention to be ready to win in any biowarzone, the US military has commissioned Dynavax to develop a vaccine for the plague.

A possible fix for problems in small molecule manufacture via continuous flow processing.

Setting its sights on self-amplifying RNA, AstraZeneca has signed a deal with Imperial College London spinoff VaxEquity.